If you need more lookups,
subscriptions start at $34 USD/month.
Peter Atadja Location
Boston, MA, US
Peter Atadja Work
2024 -now Chief Scientific Officer @
2023 -2023 Chief Scientific Advisor @
2009 -2020 Executive Director and Head, Drug Discovery at Novartis Institutes for BioMedical Research (NIBR) @
2005 -2015 Head, Epigenetics Drug Discovery and Scientific Lead Global Panobinostat Dev. Team @
2003 -2009 Director, Epigenetics Drug Discovery @
Peter Atadja Education
University of Calgary 1991-1995
Hebrew University of Jerusalem
Masters (Chemistry)
1988-1991
Kwame Nkrumah University of Science and Technology
Kpando Secondary School
Peter Atadja Skills
Research and Development (R&D)
Oncology
Research
Validation
Drug Design
Hematologic Malignancies
Small molecular weight, Antibody-Drug Conjugate and CART drug discovery (Disease Biology Research, target discovery & Validation, Hit to lead discovery, Lead optimization, Pharmacology, biomarker discovery and validation, Coordinating Pre-GLP, GLP and Pre-IND Tox and DMPK studies and reports, Scientific leadership of design and execution of phase I, II and III clinical studies and commercial launch.
Pharmacokinetics
Clinical Trials
ADME
Biochemistry
Biomarkers
Biotechnology
Cancer
Drug Development
Drug Discovery
Life Sciences
Medicinal Chemistry
Molecular Biology
Pharmaceutical Industry
Target Identification
Clinical Development
HPLC
Immunology
Lead Change
Lifesciences
Pharmacology
Peter Atadja Summary
Peter Atadja, based in Boston, MA, US, is currently a Chief Scientific Officer at Landcent Europe. Peter Atadja brings experience from previous roles at Landcent Europe and Novartis. Peter Atadja holds a 1991 - 1995 University of Calgary. With a robust skill set that includes Research and Development (R&D), Oncology, Research, Validation, Drug Design and more. Peter Atadja has 2 emails and 1 mobile phone numbers on RocketReach.
Looking for a different Peter Atadja?
Find contact details for 700 million professionals.